Nancy D. Lin
YOU?
Author Swipe
View article: Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States Open
Trastuzumab biosimilars utilization has grown since their introduction to the US market. Exploration of these biosimilars' comparative effectiveness and safety to their reference product is warranted.
View article: Considerations for defining medication exposure when analyzing <scp>real‐world</scp> data
Considerations for defining medication exposure when analyzing <span>real‐world</span> data Open
Medication use is a crucial component of drug safety and efficacy studies.1 Although there have been successful attempts to define medication use, these efforts have mostly concentrated on specific applications within certain analyses.2-5 …
View article: Trends in COVID-19 patient characteristics in a large electronic health record database in the United States: A cohort study
Trends in COVID-19 patient characteristics in a large electronic health record database in the United States: A cohort study Open
Background Electronic health record (EHR) databases provide an opportunity to facilitate characterization and trends in patients with COVID-19. Methods Patients with COVID-19 were identified based on an ICD-10 diagnosis code for COVID-19 (…
View article: Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants
Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants Open
ClinicalTrials.gov Identifier: NCT03259373.
View article: Predictors of critical care, mechanical ventilation, and mortality among hospitalized patients with COVID-19 in an electronic health record database
Predictors of critical care, mechanical ventilation, and mortality among hospitalized patients with COVID-19 in an electronic health record database Open
Background There are limited data on risk factors for serious outcomes and death from COVID-19 among patients representative of the U.S. population. The objective of this study was to determine risk factors for critical care, ventilation, …
View article: Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib)
Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib) Open
View article: Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial
Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial Open
IMPACT-AFib was an 80,000-patient randomized clinical trial implemented by five US insurance companies (health plans) aimed at increasing the use of oral anticoagulants by individuals with atrial fibrillation who were at high risk of strok…
View article: Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States
Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States Open
Despite a lower TD prevalence than previously estimated and the predominant use of atypical antipsychotics, identified TD patients appear to have a substantial comorbidity burden that requires special treatment and management consideration.
View article: FDA-Catalyst—Using FDA’s Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial
FDA-Catalyst—Using FDA’s Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial Open
Background: The US Food and Drug Administration’s Sentinel Initiative is well positioned to support pragmatic clinical trials. FDA-Catalyst combines direct contact with health plan members and/or providers with data in the Sentinel infrast…
View article: Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females
Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females Open
After the Food and Drug Administration (FDA) licensed quadrivalent human papillomavirus vaccine (HPV4) in 2006, reports suggesting a possible association with venous thromboembolism (VTE) emerged from the Vaccine Adverse Event Reporting Sy…
View article: Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database
Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database Open
Our findings, while not statistically significant, may suggest a higher incidence of hepatic injury other than hepatic-related death or liver failure among duloxetine initiators compared to venlafaxine and possibly SSRIs, but not untreated…